Advertisement

Loading...

Cassiopea S.p.A.

SKIN.SWSIX
Healthcare
Biotechnology
CHF35.70
CHF3.20(9.85%)
Swiss Market opens in 0h 34m

Cassiopea S.p.A. Fundamental Analysis

Cassiopea S.p.A. (SKIN.SW) shows weak financial fundamentals with a PE ratio of -32.77, profit margin of 0.00%, and ROE of -1.27%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.30
Current Ratio1.98

Areas of Concern

ROE-1.27%
Operating Margin0.00%
We analyze SKIN.SW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -123.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-123.6/100

We analyze SKIN.SW's fundamental strength across five key dimensions:

Efficiency Score

Weak

SKIN.SW struggles to generate sufficient returns from assets.

ROA > 10%
-66.08%

Valuation Score

Excellent

SKIN.SW trades at attractive valuation levels.

PE < 25
-32.77
PEG Ratio < 2
-0.30

Growth Score

Weak

SKIN.SW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

SKIN.SW maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
1.98

Profitability Score

Weak

SKIN.SW struggles to sustain strong margins.

ROE > 15%
-127.27%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is SKIN.SW Expensive or Cheap?

P/E Ratio

SKIN.SW trades at -32.77 times earnings. This suggests potential undervaluation.

-32.77

PEG Ratio

When adjusting for growth, SKIN.SW's PEG of -0.30 indicates potential undervaluation.

-0.30

Price to Book

The market values Cassiopea S.p.A. at 25.83 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

25.83

EV/EBITDA

Enterprise value stands at -0.22 times EBITDA. This is generally considered low.

-0.22

How Well Does SKIN.SW Make Money?

Net Profit Margin

For every $100 in sales, Cassiopea S.p.A. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-1.27 in profit for every $100 of shareholder equity.

-1.27%

ROA

Cassiopea S.p.A. generates $-66.08 in profit for every $100 in assets, demonstrating efficient asset deployment.

-66.08%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.96 in free cash annually.

$-0.96

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-32.77

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.30

vs 25 benchmark

P/B Ratio

Price to book value ratio

25.83

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.004

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.27

vs 25 benchmark

ROA

Return on assets percentage

-0.66

vs 25 benchmark

ROCE

Return on capital employed

-0.70

vs 25 benchmark

How SKIN.SW Stacks Against Its Sector Peers

MetricSKIN.SW ValueSector AveragePerformance
P/E Ratio-32.7728.31 Better (Cheaper)
ROE-127.27%699.00% Weak
Net Margin0.00%-130884.00% (disorted) Weak
Debt/Equity0.000.34 Strong (Low Leverage)
Current Ratio1.982775.16 Neutral
ROA-66.08%-14469.00% (disorted) Weak

SKIN.SW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Cassiopea S.p.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ